Senzime’s Earnings Call Highlights NextGen Momentum, 2026 Pivot

Senzime AB ((SE:SEZI)) has held its Q4 earnings call. Read on for the main highlights of the call.

Senzime’s latest earnings call struck a cautiously upbeat tone, emphasizing strong commercial traction for its NextGen TetraGraph platform and expanding global footprint, while acknowledging FX headwinds, regulatory delays, and one‑off costs that weighed on reported results. Management stressed that underlying demand and usage trends remain robust and reiterated confidence in the path to cash‑flow breakeven.

Q4 Sales and System Installations

Senzime reported Q4 sales of SEK 28.3 million and 416 new TetraGraph systems installed, confirming solid uptake despite some timing effects. Management noted that installation volumes were below certain earlier quarters largely because several sizeable contracts slipped into January and U.S. hospital purchasing showed typical year‑end seasonality.

NextGen Platform Adoption and Utilization

The NextGen TetraGraph platform remained the main growth engine, with customers upgrading from Classic seeing over 50% increases in device utilization. This surge in use translates into higher recurring revenue from disposables and serves as a validation of the platform’s clinical benefits in neuromuscular monitoring.

Geographic Expansion and Regulatory Progress

International momentum continued, with notable uptake in Asia and Europe during Q4 as more hospitals standardized on EMG‑based monitoring. The company secured PMDA approval in Japan in December 2025, enabling initial shipments, while South Korea is already showing rapid “double‑digit” conversion despite full regulatory approval now expected only by mid‑ to late‑2026.

‘TetraGraph as a Service’ Model in the U.S.

A new U.S. “TetraGraph as a Service” placement model is reshaping how Senzime sells monitors, cutting the sales cycle roughly in half. Because Senzime retains ownership of the instruments and charges a premium for sensors, this model is expected to accelerate deployments and support structurally higher long‑term gross margins.

Balance Sheet Strength and Liquidity Support

To underpin its growth investments, the company secured a SEK 50 million credit facility aimed at smoothing working capital peaks and inventory requirements. Management highlighted that the facility is on what it views as fair market terms and does not include dilutive features, lowering the likelihood of near‑term equity financing.

IP Portfolio and R&D Pipeline

Senzime underlined its technology moat, citing 107 granted patents and eight additional patent filings during 2025. Ongoing R&D focuses on new software capabilities and adjacent respiratory monitoring solutions, including work linked to the RMI ExSpiron platform, which together are designed to broaden the product ecosystem.

Manufacturing Capacity and Supply Localization

Monitor production is handled in‑house at the company’s Uppsala facility, which management says can support the next five years of its business plan. Disposable sensors are produced with partners, and Senzime is shifting key sub‑supplies from Asia to Europe and Scandinavia to localize the chain and improve resilience.

Profitability Trajectory and Cost Base

The company reiterated its target to reach cash‑flow positivity by Q4 2026, positioning 2026 as a transition year toward better profitability. Operating expenses are expected to be flat or lower compared with 2025, with Q4’s SEK 4–5 million of event‑driven and commission‑related one‑offs not anticipated to repeat.

Full‑Year Sales Shortfall and FX Effects

Reported full‑year revenue landed below the previously guided SEK 110–140 million range, but management attributed this mainly to a weaker U.S. dollar and euro. On a fixed‑currency basis, they said full‑year sales would have been within the guided corridor, suggesting underlying commercial performance tracked internal expectations.

Regulatory Delays and Near‑Term Revenue Timing

The earnings call acknowledged that slower‑than‑planned regulatory processes in Japan and South Korea pushed some expected revenue into later periods. While Japan’s PMDA approval finally came through in December, South Korea’s full regulatory clearance is now anticipated sometime in mid‑ to late‑2026, extending the ramp‑up profile in that market.

Inventory Write‑Down from Classic to NextGen Shift

As Senzime phases out the TetraGraph Classic in favor of the NextGen platform, it took an inventory write‑down on older raw materials and components. The non‑cash charge, booked in 2025 cost of goods sold, reflects the company’s decision to accelerate the transition toward its more profitable and clinically advanced system.

Q4 Operating Expense Spike and One‑Off Costs

Operating expenses jumped in Q4 versus Q3, driven by roughly SEK 4–5 million in one‑time items such as major marketing events, congress participation, and related sales commissions. These expenditures compressed quarterly profitability, but management emphasized they were exceptional and not indicative of the ongoing cost base.

Timing Variability in Installations

The 416 new monitors placed in Q4 looked softer compared with certain earlier quarters, but management framed the shortfall as largely a timing issue. Several large contracts closed just after year‑end, and U.S. hospitals showed usual purchasing seasonality, suggesting no structural slowdown in customer interest.

Working Capital and CapEx Under the Service Model

The shift to owning instruments under the service model means Senzime must commit more capital upfront, tying working capital and CapEx more closely to installed base growth. Management views these higher near‑term capital needs as an acceptable trade‑off for recurring revenue streams and structurally better margins over time.

Forward‑Looking Guidance and Outlook

Looking ahead, Senzime guided to continued growth in 2026 at a similar rate to recent years, driven by NextGen adoption, geographic expansion, and the service model. The company expects operating expenses to stay flat or fall versus 2025 and continues to target becoming cash‑flow positive by Q4 2026, despite FX uncertainty and staggered regulatory timelines.

Senzime’s earnings call painted a picture of a medtech company trading near‑term volatility for longer‑term quality of growth. With strong NextGen utilization, expanding international approvals, and a higher‑margin service model, investors are being asked to look through FX noise and timing issues to a 2026 inflection in cash generation and profitability.